Franklin Biotechnology Discv N(acc)PLNH1 |
Performance History | 30/04/2024 |
Growth of 1,000 (EUR) |
Fund | - | -19.3 | -13.2 | 26.7 | 4.2 | |
+/-Cat | - | - | - | - | - | |
+/-Idx | - | - | - | - | - | |
Category: Other Equity | ||||||
Benchmarks: - |
Key Stats | ||
NAV 16/05/2024 | PLN 9.82 | |
Day Change | -0.14% | |
Morningstar Category™ | Other Equity | |
ISIN | LU2251237215 | |
Fund Size (Mil) 30/04/2024 | USD 1625.86 | |
Share Class Size (Mil) 16/05/2024 | PLN 14.89 | |
Max Initial Charge | 3.00% | |
Ongoing Charge 04/03/2024 | 2.56% |
Investment Objective: Franklin Biotechnology Discv N(acc)PLNH1 |
The Fund’s investment objective is capital appreciation. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Evan McCulloch 01/11/2000 | ||
Wendy Lam 01/09/2018 | ||
Click here to see others | ||
Inception Date 12/11/2020 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Franklin Biotechnology Discv N(acc)PLNH1 | 30/04/2024 |
|
|
Top 5 Holdings | Sector | % |
Amgen Inc | Healthcare | 7.08 |
Regeneron Pharmaceuticals Inc | Healthcare | 6.34 |
Vertex Pharmaceuticals Inc | Healthcare | 5.39 |
Ascendis Pharma A/S ADR | Healthcare | 4.07 |
AstraZeneca PLC ADR | Healthcare | 3.69 |
Increase Decrease New since last portfolio | ||
Franklin Biotechnology Discv N(acc)PLNH1 |